Tag
AbbVie
4 articles
AbbVie's Vraylar Heads for IRA Price Cut in 2027; Imbruvica Already Down 26 Percent
AbbVie warned investors to model lower prices for its $4.2 billion psychiatry drug Vraylar starting in 2027 under Medicare price negotiation, as its cancer drug Imbruvica faces a 26 percent sales cliff from IRA pricing.
AbbVie Raises FY Guidance on Skyrizi, Rinvoq Momentum
AbbVie beat Q3 EPS and revenue estimates, raising full-year adjusted EPS guidance to $13.95-$13.99 on strength in immunology franchises
AbbVie's Juvmo Approval Validates $8.7B Cerevel Bet, Eyes $1.4B Peak Sales
FDA approval of Juvmo, AbbVie's once-daily Parkinson's treatment, delivers near-term validation of its Cerevel acquisition and positions a new growth driver as Humira patent cliff deepens.
AbbVie's Aesthetics Unit Gains From Korea's Cosmetic Surgery Boom
South Korea's expanding cosmetic surgery market signals strong growth for U.S. medical aesthetics companies like AbbVie